-
Mashup Score: 0Webprogram Unavailable - 11 month(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - NSCLC - 2023 Lung Cancer Mortality Predictions in Europe - 11 month(s) ago
By: Lauren Velentzas Posted: Friday, May 12, 2023 Carlo La Vecchia, MD, of the University of Milan, Italy, and colleagues have predicted that rates for deaths attributable to lung cancer will continue to fall overall in the five most populous European Union countries—France, Germany, Italy, Poland, and Spain—and the…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
2023 #LungCancer Mortality Predictions in Europe: https://t.co/eUQsiJ1JTx #JNCCN360 #LCSM #globonc https://t.co/I80CEhmGwh
-
-
Mashup Score: 1Webprogram Unavailable - 12 month(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study [Dec 10, 2022] @NoemiPuigM et al. @BerdejaJesus Abs 1859 #ASH22 https://t.co/mCCkPgMebV #mmsm #globonc https://t.co/uDpGCoIm73
-
-
Mashup Score: 1JNCCN 360 - BiomarkerNTRK - AACR 2023: Finnish Population–Based Study of NTRK Gene Fusions in Solid Tumors - 1 year(s) ago
By: Emily Rhode Posted: Tuesday, April 25, 2023 Merja Perälä, MD, of the University of Turku and Turku University Hospital, Finland, and colleagues conducted a retrospective cohort study to investigate the frequency of NTRK gene fusions in patients with solid tumors from a population-based setting in the Turku region…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#AACR23: Finnish Population–Based Study of #NTRK Gene Fusions in Solid Tumors: https://t.co/TMPx5xyCiJ #globonc #JNCCN360 https://t.co/l95duXgygO
-
-
Mashup Score: 0Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy - 1 year(s) ago
This cohort study investigates survival rates for non–small cell lung cancer in Korea from 2010 to 2020 with use of molecular testing and targeted therapy.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020 [Mar 16, 2023] Sang Ah Chi et al. @JAMANetworkOpen https://t.co/BmIhfOpyQY #lcsm #PrecisionMedicine #globonc n= 21 ,978 patients https://t.co/euiiMxkVBV
-
-
Mashup Score: 0JNCCN 360 - B-Cell Lymphomas - R-CHOP as Front-Line Therapy for Primary Mediastinal LBCL: A View From Jordan - 1 year(s) ago
By: Emily Rhode Posted: Tuesday, April 4, 2023 Mohammad Ma’koseh, MD, of the King Hussein Cancer Center, Amman, Jordan, and colleagues assessed the efficacy of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as a front-line therapy for adults with primary mediastinal large B-cell…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
R-CHOP as Front-Line Therapy for Primary Mediastinal Large B-Cell #Lymphoma: A View From Jordan: https://t.co/zzw2px70OX #JNCCN360 #GlobOnc #lymsm #LBCL https://t.co/bOAavsA13Q
-
-
Mashup Score: 12Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet-
There is a lot to learn from what happened during the height of #COVID19!!! Vulnerable populations like #gerionc patients should be protected during emergencies. 👉 Ensure care continuity 👉Financial protection Awesome to work with such a great team! https://t.co/BesDdywOdC
-
We also looked at the main difficulties linking #COVID19 and #cancer care #gerionc Patients reported barriers for accessing cancer care, limited medication availability and financial issues including food insecurity🍽️ https://t.co/BesDdywOdC https://t.co/KKx9UcRJsU
-
In this work, led by @SofiSanR and funded by @ConquerCancerFd we evaluated the concerns of 🇲🇽older adults with cancer #gerionc at the height of the pandemic. The main concern was getting #COVID19 followed by financial issues and delays in care https://t.co/BesDdywOdC https://t.co/8C9Jil2D9g
-
Check out our most recent @jgerionc manuscript on the concerns and difficulties faced by older patients with cancer during the #COVID19 pandemic in #Mexico 🇲🇽 @SofiSanR @incmnszmx #gerionc #geriheme #globonc 👇👇👇👇👇👇👇👇👇 https://t.co/BesDdywOdC https://t.co/TMrzAVyA7a
-
-
Mashup Score: 3
ASCO is pleased to announce the leaders selected for the 2023-2024 Leadership Development Program Asia Pacific (LDP-AP).
Source: ASCO ConnectionCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🙌 Congratulations to the 12 leaders selected for the 2023-2024 Leadership Development Program Asia Pacific! We’re looking forward to hearing their ideas and watching them develop into guiding forces in our field. https://t.co/cqYxdmK9pl #OncTwitter #globonc #ASCO_LDP_AP https://t.co/79ZYVYG9gI
-
-
Mashup Score: 0Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy - 1 year(s) ago
This cohort study investigates survival rates for non–small cell lung cancer in Korea from 2010 to 2020 with use of molecular testing and targeted therapy.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020 [Mar 16, 2023] Sang Ah Chi et al. @JAMANetworkOpen https://t.co/BmIhfOpyQY #lcsm #PrecisionMedicine #globonc n= 21, 978 patients https://t.co/QjRbOvmWuk
-
-
Mashup Score: 1
Oral and Poster Abstracts 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I Research, adult, Clinical Research, Plasma Cell Disorders, Diseases, real-world evidence, Lymphoid Malignancies, Study Population, Human Noemi Puig, MD, PhD1*, Vania T. M. Hungria, MD, PhD2, Ajai Chari3*, Faith E. Davies, MD4*, Gordon Cook5*,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study [Dec 10, 2022] @NoemiPuigM et al. @BerdejaJesus Abs 1859 #ASH22 https://t.co/mCCkPgMebV #mmsm #globonc https://t.co/zbIYFnacgJ
-
Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study [Dec 10, 2022] @NoemiPuigM et al. @BerdejaJesus Abs 1859 #ASH22 https://t.co/mCCkPgMebV #mmsm #globonc https://t.co/SbV7lfv3tJ